How RYSTIGGO works

RYSTIGGO is a targeted treatment for
generalized myasthenia gravis (gMG)

How RYSTIGGO works

RYSTIGGO is a targeted treatment for
generalized myasthenia gravis (gMG)

Understanding how RYSTIGGO works in gMG

 

In gMG, harmful anti-AChR or anti-MuSK antibodies can get in the way of signals between nerves and certain receptors on muscles.

In the neuromuscular junction, where nerves and muscles meet, this loss of signaling can lead to muscle weakness, fatigue, shortness of breath, and other gMG symptoms.

AChR=acetylcholine receptor; MuSK=muscle-specific tyrosine kinase.

In gMG, harmful antibodies interrupt signaling at the neuromuscular junction.
In gMG, harmful antibodies interrupt signaling at the neuromuscular junction.

These harmful antibodies can continue to stay in your system because of an immune system protein called FcRn (neonatal Fc receptor).

 

FcRn can extend the life of certain antibodies, including anti-AChR and anti-MuSK antibodies, by preventing them from being broken down by your cells' natural waste clearance system.

FcRN allows harmful antibodies to be recycled.
FcRN allows harmful antibodies to be recycled.

RYSTIGGO AT WORK

RYSTIGGO works by specifically targeting FcRn and blocking it from extending the life of these harmful antibodies.

This helps ensure they are broken down in the cell normally.

RYSTIGGO binds to FcRn, blocking harmful antibodies from being recycled.
RYSTIGGO binds to FcRn, blocking harmful antibodies from being recycled.

During a RYSTIGGO treatment cycle, there are fewer harmful antibodies in the way of signaling between nerves and muscles.

Individual results may vary, and not all people will experience improvements.

With RYSTIGGO, fewer harmful antibodies interrupt signaling at the neuromuscular junction.
With RYSTIGGO, fewer harmful antibodies interrupt signaling at the neuromuscular junction.

Ask your doctor if RYSTIGGO may be right for you.

Our Doctor Discussion Guide can help you get the conversation started.